HU-014

Phase 3Biologic

HHuons Co., Ltd.

HU-014 is one of 60 biologic programs targeting Spasticity. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

SpasticityActive, not recruiting

StrokeActive, not recruiting

SpasticityPhase 1

Active, not recruiting

StrokePhase 3

Active, not recruiting

Competition

Competitive Landscape

461 competitors in Stroke

#DrugCompanyPhaseTrials

HU-014

HHuons Co., Ltd.

Phase 3

1 2

Zometa

Pfizer

Preclinical

1 3

Folvite

Eli Lilly

Preclinical

1 4

Proamatine

Repatha

Pradaxa

3 7

Botox

RRevance Therapeutics, Inc.

Preclinical

2 8

Periactin

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 9

Alka-Seltzer

AAbbott

Preclinical

1 10

Haldol

DDePuy Orthopaedics

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Safety and Efficacy1 trial

A Phase 1/3 Clinical Trial to Evaluate the Safety and Efficacy of HUTOX Compared to Botox® in Subjects With Moderate to Severe Crow's Feet Lines

Unknown status·HHuons Co., Ltd.·Phase 3·NCT04081402·290 enrolled

Stroke1 trial

To Evaluate HU-014 in the Treatment of Post Stroke Upper Limb

Completed·HHuons Co., Ltd.·Phase 3·NCT05289921·198 enrolled

Moderate to Severe Glabellar Lines1 trial

The Safety and Efficacy Study of HU-014 Versus Botox® in Subject With Moderate to Severe Glabellar Lines

Completed·HHuons Co., Ltd.·Phase 1/2·NCT02961673·57 enrolled

Spasticity1 trial

A Single Center, Phase I Clinical Trial to Evaluate the Safety of LIZTOX Inj in the Treatment of Post Stroke Upper Limb Spasticity

Unknown status·HHuons Co., Ltd.·Phase 1·NCT04415346·13 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for HU-014. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — HU-014 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for HU-014. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Huons Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 3[1]
Company: HHuons Co., Ltd.

HU-014

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Safety and Efficacy1 trial

Stroke1 trial

Moderate to Severe Glabellar Lines1 trial

Spasticity1 trial

References

Drug Info

Quick Facts

Related News